Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 4:39 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 79 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Xifaxan Clear all

Conditions: Hepatic Encephalopathy
Interventions: Rifaximin, Lactulose, Placebo; Drug · Other
Lead sponsor: University of Miami; Other
Eligibility: 18 Years and older
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Hepatic Encephalopathy
Interventions: Rifaximin SSD, Placebo; Drug
Lead sponsor: Bausch Health Americas, Inc.; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 524 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 139
States / cities: Dothan, Alabama • Chandler, Arizona • Peoria, Arizona + 103 more

Conditions: Hepatic Encephalopathy
Interventions: Rifaximin; Other
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: New York, New York

Conditions: Hepatic Encephalopathy
Interventions: Rifaximin; Drug
Lead sponsor: Bausch Health Americas, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 322 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 31
States / cities: Birmingham, Alabama • Aurora, California • Fresno, California + 28 more

Conditions: Small Intestinal Bacterial Overgrowth
Interventions: CapScan collection capsule; Device
Lead sponsor: Envivo Bio Inc; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Mountain View, California

Conditions: Visceral Hypersensitivity, Irritable Bowel Syndrome
Interventions: Rifaximin; Drug
Lead sponsor: Cedars-Sinai Medical Center; Other
Eligibility: 18 Years to 75 Years
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Sickle Cell Disease, Antibiotics
Interventions: Rifaximin; Drug
Lead sponsor: New York Medical College; Other
Eligibility: 18 Years to 70 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Valhalla, New York

Conditions: Diarrhea
Interventions: Rifaximin, Xifaxan®, Placebo Tablet; Drug
Lead sponsor: Actavis Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 739 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Coral Gables, Florida

Conditions: Parkinson's Disease
Interventions: Rifaximin; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: Scottsdale, Arizona

Conditions: Crohn Disease, Diabetic Gastroparesis
Interventions: Rifaximin, Placebo; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 75 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Clostridium Infections, Diarrhea
Interventions: Rifaximin (Xifaxan), Vancomycin; Drug
Lead sponsor: Bausch Health Americas, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 237 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 63
States / cities: Scottsdale, Arizona • Redlands, California • Longmont, Colorado + 54 more

Conditions: Irritable Bowel Syndrome
Interventions: Rifaximin; Drug
Lead sponsor: Bausch Health Americas, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 525 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 67
States / cities: Scottsdale, Arizona • Tempe, Arizona • Anaheim, California + 61 more

Conditions: Rectal Cancer
Interventions: Rifaximin, Placebo; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 21 Years and older
Enrollment: 69 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2023
U.S. locations: 3
States / cities: Basking Ridge, New Jersey • Commack, New York • New York, New York

Conditions: Non-Constipation Irritable Bowel Syndrome
Interventions: Rifaximin, Placebo; Drug
Lead sponsor: Bausch Health Americas, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 637 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 88
States / cities: Anniston, Alabama • Birmingham, Alabama • Huntsville, Alabama + 83 more

Conditions: HIV
Interventions: Rifaximin, Placebo; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 3
States / cities: Bethesda, Maryland • Pittsburgh, Pennsylvania

Conditions: Hepatic Encephalopathy, Cirrhosis
Interventions: Microbiota transplant therapy (MTT) capsules, Placebo capsule; Biological · Other
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 21 Years and older
Enrollment: 162 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 3
States / cities: West Haven, Connecticut • Dallas, Texas • Richmond, Virginia

Conditions: Crohn's Disease
Interventions: Fecal Microbial transplant, Normal Saline, rifaximin+omeprazole+miralax; Biological · Drug
Lead sponsor: Seattle Children's Hospital; Other
Eligibility: 12 Years to 21 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Crohn's Disease
Interventions: Fludarabine, Cyclophosphamide, Mesna, Alemtuzumab, G-CSF, Rifaximin, Tacrolimus; Drug
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 49 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Non-Constipation Irritable Bowel Syndrome
Interventions: Rifaximin, Placebo; Drug
Lead sponsor: Bausch Health Americas, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 623 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 86
States / cities: Hueytown, Alabama • Phoenix, Arizona • Sierra Vista, Arizona + 78 more

Conditions: Parkinson Disease
Interventions: Rifaximin, Placebo; Drug · Other
Lead sponsor: University of California, San Francisco; Other
Eligibility: 30 Years and older
Enrollment: 86 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Hepatic Encephalopathy
Interventions: Placebo, Rifaximin; Drug
Lead sponsor: Bausch Health Americas, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 28
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 22 more

Conditions: Intestinal FDG Uptake
Interventions: Rifaximin; Drug
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Obese, Insulin Resistance, Metabolic Syndrome
Interventions: Rifaximin SSD, Placebo; Drug · Other
Lead sponsor: Philip Kern; Other
Eligibility: 35 Years to 65 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: Functional Dyspepsia, Small Intestinal Bacterial Overgrowth, Chronic Abdominal Discomfort
Interventions: Rifaximin, Lactulose Breath Test, Placebo; Drug · Procedure
Lead sponsor: Henry C. Lin, MD; Federal
Eligibility: 21 Years and older
Enrollment: 55 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2007
U.S. locations: 1
States / cities: Albuquerque, New Mexico

Search by objective public record fields.

RICE Trial: Rifaximin In Chronic Hepatic Encephalopathy - A Randomized, Controlled Trial

Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis

The Role of Bacterial Overgrowth and Delayed Intestinal Transit in Hepatic Encephalopathy.

Safety and Tolerability Study of Rifaximin in Participants With a History of Hepatic Encephalopathy

Evaluating the Effect Of Rifaximin on the Gut Microbiota and Metabolome in SIBO Using CapScan®

Rifaximin on Visceral Hypersensitivity

Rifaximin to Modify the Disease Course in Sickle Cell Disease

Study Comparing Rifaximin With Xifaxan 200 mg in Traveler's Diarrhea

Weight Loss in Parkinson's Disease and Role of Small Bowel Bacterial Overgrowth

Rifaximin in Patients With Diabetic Gastroparesis

A Trial to Compare Xifaxan to Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD)

Study to Assess the Efficacy and Safety of Rifaximin Administered BID in the Treatment of Patients With Diarrhea-Associated Irritable Bowel Syndrome

Rifaximin and Placebo in the Treatment of Bowel Dysfunction After Anterior Resection for Rectal Cancer

Rifaximin 3 Times/Day (TID) for Non-Constipation Irritable Bowel Syndrome (IBS)

Rifaximin for Chronic Immune Activation in People With HIV

Microbiota trAnSplant ThERaPy In hEpatiC Encephalopathy (MASTERPIECE)

Fecal Microbial Transplant in Pediatric Crohn's Disease

Autologous Transplant Targeted Against Crohn's

Rifaximin 3 Times/Day (TID) for Non-Constipation Irritable Bowel Syndrome (IBS)

Microbiota Intervention to Change the Response of Parkinson's Disease

Efficacy, Safety, And Pharmacokinetics Of Rifaximin In Subjects With Severe Hepatic Impairment And Hepatic Encephalopathy

A Clinical Study to Limit Physiologic Intestinal FDG Uptake Uptake on PET-CT Scans

Blood Lipopolysaccharide (LPS) Rifaximin Study

Does Small Intestinal Bacterial Overgrowth Contribute to Functional Dyspepsia